Clinical Trials Logo

Clonal Hematopoiesis clinical trials

View clinical trials related to Clonal Hematopoiesis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05705531 Recruiting - Hodgkin Lymphoma Clinical Trials

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Start date: August 18, 2023
Phase:
Study type: Observational

This study assesses how blood cell growth patterns (clonal hematopoiesis), relates to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.

NCT ID: NCT04689750 Recruiting - Clinical trials for Clonal Hematopoiesis

Donor CHIP and Allogeneic HSCT Outcome

Start date: January 1, 2021
Phase:
Study type: Observational

Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft versus host disease (GVHD), disease relapse and survival across various donor populations are scarce. This is a retrospective-prospective cohort study designed to determine the association between donor gene mutations and outcome following allogeneic HSCT.

NCT ID: NCT04541654 Recruiting - Clinical trials for Li-Fraumeni Syndrome

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

LiFT_UP
Start date: September 15, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).